Your browser doesn't support javascript.
loading
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
Uraki, Ryuta; Ito, Mutsumi; Kiso, Maki; Yamayoshi, Seiya; Iwatsuki-Horimoto, Kiyoko; Furusawa, Yuri; Sakai-Tagawa, Yuko; Imai, Masaki; Koga, Michiko; Yamamoto, Shinya; Adachi, Eisuke; Saito, Makoto; Tsutsumi, Takeya; Otani, Amato; Kikuchi, Tetsuhiro; Yotsuyanagi, Hiroshi; Halfmann, Peter J; Pekosz, Andrew; Kawaoka, Yoshihiro.
Afiliação
  • Uraki R; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Ito M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Kiso M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Yamayoshi S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Iwatsuki-Horimoto K; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Furusawa Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Sakai-Tagawa Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Imai M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Koga M; Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Yamamoto S; Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Adachi E; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Saito M; Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Tsutsumi T; Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Otani A; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Kikuchi T; Clinic of Nihon Sumo Kyokai, Tokyo, Japan.
  • Yotsuyanagi H; Division of Infectious Diseases, Advanced Clinical Research Center, University of Tokyo, Tokyo 108-8639, Japan; Department of Infectious Diseases and Applied Immunology, Hospital of The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
  • Halfmann PJ; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Pekosz A; Department of Microbiology and Immunology, School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
  • Kawaoka Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Pandemic Preparedness, Infection and Advanced Research Center, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Res
Lancet Infect Dis ; 23(4): 402-403, 2023 04.
Article em En | MEDLINE | ID: mdl-36773622
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Antivirais / Vacinas contra COVID-19 / COVID-19 Limite: Humans Idioma: En Revista: Lancet Infect Dis Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Antivirais / Vacinas contra COVID-19 / COVID-19 Limite: Humans Idioma: En Revista: Lancet Infect Dis Ano de publicação: 2023 Tipo de documento: Article